Bergman U, Griffiths R R
Drug Alcohol Depend. 1986 Feb;16(4):293-301. doi: 10.1016/0376-8716(86)90063-3.
Results of previous laboratory studies in humans suggest that the benzodiazepine diazepam has greater abuse liability than the benzodiazepine oxazepam. The validity of these laboratory-based experimental data were examined by analyzing Swedish data on drug abuse. Sales and prescription data showed that use of diazepam was somewhat lower than oxazepam, but of the same general order of magnitude (0.8:1). Prescription data showed that the drugs were prescribed for the same diagnostic indications. After adjustment for differences in use, 'prescription forgeries' and 'mentions in theft and loss reports' were found to be more frequent for diazepam than for oxazepam (2.3:1 and 2.5:1 for forgeries and theft/loss reports, respectively). This effect was consistent for each year examined (1982, 1983, 1984) and occurred when the data were recalculated to exclude Valium, the original and most widely known brand of diazepam. Finally, this pattern with prescription forgeries occurred across different geographical regions in Sweden (1982, 1983).
先前针对人类的实验室研究结果表明,苯二氮䓬类药物地西泮比苯二氮䓬类药物奥沙西泮具有更高的滥用可能性。通过分析瑞典药物滥用数据,对这些基于实验室的实验数据的有效性进行了检验。销售和处方数据显示,地西泮的使用量略低于奥沙西泮,但总体数量级相同(0.8:1)。处方数据表明,这两种药物的处方用于相同的诊断指征。在对使用差异进行调整后,发现地西泮的“处方伪造”和“在盗窃及丢失报告中的提及”比奥沙西泮更为频繁(处方伪造为2.3:1,盗窃/丢失报告为2.5:1)。在研究的每一年(1982年、1983年、1984年),这种效应都是一致的,并且在重新计算数据以排除地西泮最初且最为人熟知的品牌安定后,这种效应依然存在。最后,这种处方伪造模式在瑞典不同地理区域(1982年、1983年)均有出现。